bluuebunny/crossref_metadata_2025_split huggingface dataset:
Immunotherapy and whole‐body hyperthermia as combined modality treatment of a subcutaneous murine sarcoma
Authors: Geehan Douglas M. , Fabian Dagmar F. , Lefor Alan T. 
Published: February 2007

AbstractInterleukin–2 and hyperthermia have been used individually to treat a variety of tumors in both experimental and human trials. Combined adoptive immunotherapy and hyperthermia is an exciting new line of investigation. Previous work in our laboratory has shown that combined local hyperthermia and rIL‐2 therapy can significantly decrease the rate of tumor growth. In this study, we investigated the effect of combined whole‐body hyperthermia (WBHT) and rIL‐2 on the growth of subcutaneous MCA‐105 murine tumors in C57BL/6 mice. Treatment of both microscopic (day 3) and macroscopic (day 10) tumors was evaluated. In the treatment of microscopic tumors, animals received either no treatment; rIL‐2 (3 × 105 IU ip tid) on days 3–7; plus WBHT(41°C for 30 min) on days 3, 5, and 7; or WBHT only on days 3, 5, and 7. In treating macroscopic tumors, animals received either no treatment; rIL‐2 on days 10–14; plus WBHT on days 10, 12, and 14; or WBHT only on days 10, 12, and 14. While combined treatment and WBHT alone had no significant effect on the growth of microscopic tumors, combined IL‐2 and WBHT significantly reduced the rate of tumor growth of macroscopic tumors. These results suggest that the tumor microenvironment plays a critical role in combined WBHT and rIL‐2 therapy, and may be due to effects of WBHT on the tumor vasculature. © 1993 Wiley‐Liss, Inc.
Expression of intercellular adhesion molecule‐1 in hepatocellular carcinoma
Authors: Torii Akihito , Harada Akio , Nakao Akimasa , Nonami Toshiaki , Ito Masafumi , Takagi Hiroshi 
Published: February 2007

AbstractThe expression of intercellular adhesion molecule‐1 (ICAM‐1) was investigated in frozen sections obtained from 40 resected liver specimens of patients with hepatocellular carcinoma using immunoperoxidase techniques and immunoelectron microscopy. ICAM‐1 was expressed in 80% of the HCC specimens on the membrane of cancer cells. In noncancerous regions characterized by cirrhosis in 28 cases and chronic hepatitis in 12 cases, ICAM‐1 was rarely expressed on hepatocytes but was expressed mainly on the endothelium of portal vessels and sinusoidal lining cells. These results suggest that expression of ICAM‐1 in hepatocellular carcinoma may be induced by malignant transformation of hepatocytes. © 1993 Wiley‐Liss, Inc.
Giant nonfunctioning islet cell tumor requiring pancreaticoduodenectomy and complete liver revascularization
Authors: Aszodi Ami , Leeming Rosemary A. , Lash Richard H. , Olsen Margaret M. , Ponsky Jeffrey L 
Published: February 2007

AbstractPancreaticoduodenectomy with revascularization of the hepatic artery and portal vein was performed on a 17‐year‐old girl with giant nonfunctioning islet cell tumor of the pancreas. She had a remote history of neonatal hypoglycemia leading to mental retardation and a right Wilms' tumor resected at 8 months. Serum pancreatic polypeptide levels were elevated. Her postoperative course was complicated by an ischemic perforation of the colon, which did not infect her prosthetic vascular grafts. The relationship between her neonatal hypoglycemia, Wilms' tumor, and subsequent islet cell neoplasm is unclear. © 1993 Wiley‐Liss, Inc.
Serum and immunohistochemical studies of NCC‐ST‐439 in breast cancer
Authors: Narita Tatsuhiko , Funahashi Hiroomi , Satoh Yasuyuki , Imai Tsuneo , Takagi Hiroshi 
Published: February 2007

AbstractIt has been thought that NCC‐ST‐439 antigen (ST‐439) is a tumor‐related carbohydrate antigen. The authors conducted serum and immunohistochemical studies to investigate the clinical significance of ST‐439 in breast cancer. The level of serum ST‐439 was elevated in advanced and recurrent breast cancers. In comparison with CEA and CA15–3, ST‐439 was superior in sensitivity but inferior in specificity to these markers. The level of serum ST‐439 showed no correlation with the levels of CEA or CA15–3. In the combination assay of these three markers, 80.6% of recurrent cases and 33.8% of primary cases were positive. Immunohistochemically, the expression of ST‐439 was observed in 28.1% of noncancerous mammary duct epithelium and in 38.1% of the cancerous portion. From the above, we concluded that ST‐439 was a tumor‐related antigen and could be a tumor marker with high sensitivity in breast cancer. © 1993 Wiley‐Liss, Inc.
Predictive value of serum CA125 following optimal cytoreductive surgery during weekly cisplatin induction therapy for advanced ovarian cancer
Authors: Hempling Ronald E. , Piver M. Steven , Natarajan Nachimuthu , Baker Trudy R. , Thompson John M. , Hicks Michael L. , Mettlin Curtis J. 
Published: February 2007

AbstractOne hundred seventy‐one patients with epithelial ovarian cancer were treated on a prospective protocol of weekly cisplatin induction (1 mg/kg weekly for four courses) followed by monthly cisplatin (50 mg/m2), Adriamycin (50 mg/m2), and cyclophosphamide (750 mg/m2). Seventy‐five patients with FIGO stage III or IV disease who underwent optimal cytoreductive surgery (<2 cm residual disease) were treated on this protocol and had weekly as well as monthly serum CA125 levels measured. A retrospective analysis was performed in order to determine if a ⩽50% fall in elevated serum CA125 levels during weekly cisplatin induction therapy would be predictive of findings at second look operation, normalization of serum CA125 levels (<35 u/ml) immediately prior to the third course of multiagent chemotherapy, and to determine the impact of such a decline on median progression‐free interval. Positive predictive values for this parameter with respect to findings at second look operation ranged between 38% and 50% (P> 0.05). Positive predictive values for this parameter with respect to normalization of serum CA125 levels immediately prior to the third course of multiagent chemotherapy ranged between 64.2% and 89.6% (P > 0.05). Logistic regression analysis demonstrated that a ⩽50% fall observed in CA125 levels during four weekly courses of chemotherapy served as an independent predictor of normalization of serum CA125 levels (<35 u/ml) following two courses of multiagent chemotherapy (P = 0.009) and improved median progression‐free interval (P = 0.04). Eighteen patients demonstrated a rise in serum CA125 levels during weekly induction cisplatin chemotherapy. Only one of these patients (5.5%) demonstrated a surgical complete response at the end of standard therapy. © 1993 Wiley‐Liss, Inc.
Second primary bladder cancer following pelvic irradiation for other malignancies
Authors: Ravi R. 
Published: February 2007

AbstractBetween 1985 and 1990, five cases of radiation‐induced bladder cancer were treated at our center. The first primary neoplasm was uterine cervical cancer in three patients, uterine endometrial cancer in one patient, and Hodgkin's disease in one patient. Additional treatment for the primary neoplasm included panhysterectomy for the patient with endometrial cancer and cyclophosphamide‐based combination chemotherapy for the patient with Hodgkin's disease. The mean age at development of bladder cancer was 60.4 years, and the average time interval between irradiation and development of bladder cancer was 14.6 years. All the bladder cancers were invasive. The treatment modalities included anterior pelvic exenteration in one patient, partial cystectomy in one patient, reirradiation in two patients, including the use of intraoperative electron therapy in one patient, and TUR plus endoscopic Nd:YAG laser treatment in one patient. Four patients are alive without disease at a mean follow‐up period of 15 months from the diagnosis of bladder cancer. © 1993 Wiley‐Liss, Inc.
Pharmacokinetics of cisplatin instilled into the pleural cavity following panpleuropneumonectomy in patients with malignant pleurisy due to lung cancer
Authors: Yasumoto Kosei , Shimokawa Toshihiro , Nagashima Akira , Hirose Nobuyuki , Nakahashi Hisashi 
Published: February 2007

AbstractThe pharmacokinetics of cisplatin instilled into the pleural cavity in patients with malignant pleurisy due to lung cancer were studied. Higher concentrations of total and free platinum in pleural effusion have been maintained for longer than 72 hours in patients who were subjected to panpleuropneumonectomy than in those who received simple drainage. Early rapid drop of total platinum within 6 hours was significant in the drainage group. Total platinum level in the serum of the panpleuropneumonectomy group gradually increased during 1–72 hours, however, that of the drainage group was highest at 1 hour after instillation and declined gradually with time. Free platinum in the serum was also present at lower concentrations in the panpleuropneumonectomy group than in the drainage group. These facts may be ascribed to the absorptive activity of parietal pleura which is present in the drainage group but absent in the panpleuropneumonectomy group. In summary, removal of the parietal pleura by panpleuropneumonectomy could cause cisplatin to be not only more active but also less toxic in patients with malignant pleurisy due to lung cancer. © 1993 Wiley‐Liss, Inc.
Intraportal injection of monoclonal antibody in nude mice bearing hepatic metastases
Authors: Rivoire Michel L. , Yoshida Kazuhiko , Voiglio Eric J. , Divgi Chaitanya R. , Niedzwiecki Donna , Chapman David , Cohen Alfred M. , Sigurdson Elin R. 
Published: February 2007

AbstractUsing a model for hepatic human colorectal carcinoma metastases in athymic mice, we compared the selective [intraportal (ip)] and systemic [intravenous (iv)] injection of radiolabeled monoclonal antibody (mAb) strongly reactive against the cell line. Percent injected dose of radiolabeled antibody per gram (%id/g) of tumor or normal tissues was measured at selected time points (up to 5 days postinjection) within 3 dose levels: 0.1, 1.0, and 2.0 micrograms (μg). At each dose level, 3–9 animals were studied in each of 3 groups: animals receiving ip injection (group HT‐29–15 ip), those receiving intravenous injection (group HT‐29–15 iv), and those receiving isotype‐matched control antibody via the intraportal route (group BL‐3 ip). Significantly greater (P< 0.005) %id/g in tumor was seen in group HT‐29–15 ip at all time points and dose levels compared to those in groups HT‐29–15 iv or BL‐3 ip. However, immediately after injection of mAb, there was no difference in tumor %id/g between groups HT‐29–15 ip and HT‐29–15 iv at the highest dose level. There was no increase in %id/g of mAb in normal liver and blood after ip injection compared to iv injection beyond day 1. Therefore ip injection resulted in higher tumor to liver and tumor to blood ratios compared to iv (P< 0.005). We conclude that delivery of mAb to hepatic metastases can be enhanced by selective injection; this has important implications in the design of future clinical trials utilizing radiolabeled mAb in the diagnosis and treatment of hepatic metastases. © 1993 Wiley‐Liss, Inc.
Characteristics of cancer patients under the age of 20 at medical centers in israel and the west bank: A preliminary study
Authors: Horn Yoav , Zippin Calvin , Salhab Abdel Razak , Horani Yousuf , Wan Mahmoud , Awad Elias 
Published: February 2007

AbstractThis paper describes the demographic experience on 373 young cancer patients (less than 20 years of age) at two oncology centers initiated in Israel by one medical team in 1975–1977. These units are the Assaf Harofeh Medical Center (AHMC), which predominantly serves a Jewish population (103 cases); and the West Bank Cancer Unit (WBCU), which provides similar care services to the Arab population of the West Bank (270 cases). The two centers have the unique feature of serving two populations residing in close relationship but still differing in many cultural and socioeconomic characteristics. The Arab patients at WBCU tended to be younger than the Jewish children at AHMC. The five most common diagnostic sites for both AHMC and WBCU included hematopoietic system, bones and joints, soft tissue, urinary tract, and brain and nervous system, although not in the same order of occurrence. These tumor sites accounted for approximately 80% of the cases at each center.The experience with WBCU patients was also compared with data for all Jews in Israel. This comparison identified for both sexes combined statistically significant differences in relative frequency of tumors of soft tissue, eye and orbit, brain and nervous system, and thyroid gland. If confirmed by additional data, reasons for the suggested excess risks should be pursued through more definitive epidemiological studies. © 1993 Wiley‐Liss, Inc.
Stage I testicular tumours: The tata memorial hospital experience
Authors: Tongaonkar Hemant B. , Dalal Amish V. , Kelkar Dhananjay S. , Kulkarni Jagdeesh N. , Kamat Murali R. 
Published: February 2007

AbstractOne hundred and fifty‐six patients with stage I testicular germ cell tumours—81 seminomas and 75 nonseminomatous tumours—were treated at the Tata Memorial Hospital, Bombay over a 5 year period. Among the seminomas, 71 were treated with post‐orchidectomy prophylactic radiation therapy to the retroperitoneum and/or mediastinum, while 10 patients refused radiation therapy and were put on surveillance. The disease‐free and total survival in seminomas were 92.6% and 100%, respectively. Among the patients with nonseminomatous tumours, 58 had normal levels of serum biomarkers while 17 had raised biomarkers. In the normal marker group, 20 patients underwent retroperitoneal lymph node dissection (RPLND) with a nodal positivity of 30%, while the other 38 patients refused surgery and were either placed on unplanned surveillance (33 patients) or chemotherapy (5 patients). In this group, the patients undergoing RPLND had a survival rate of 100% as compared to 93.9% in those with surveillance. The overall disease‐free and total survival rates in patients with normal markers were 86.2% and 96.6%, respectively. In the raised marker group, 6 patients underwent RPLND with a survival rate of 100% and 11 patients received chemotherapy with a survival of 90%, with the overall survival for patients with raised markers being 94.1%. The overall disease‐free and total survival rates for all patients with stage I nonseminomatous tumours were 88% and 96%, respectively. © 1993 Wiley‐Liss, Inc.
Application of the adenosine triphosphate‐cell viability assay in human breast cancer chemosensitivity testing: A report on the first results
Authors: Koechli Ossi R. , Avner Barry P. , Sevin Bernd‐Uwe , Avner Belina , Perras James P. , Robinson David S. , Averette Hervy E. 
Published: February 2007

AbstractChemosensitivity testing in vitro of breast cancer has been difficult because of small tumor volume, an even smaller yield of viable cells after disaggregation, and the low evaluability rate and sensitivity of current assays. We have employed an alternative approach that quantitates intracellular adenosine triphosphate (ATP) as a measure of cell viability. This ATP‐cell viability assay (ATP‐CVA) determines in vitro tumor cell viability after exposure to chemotherapeutic agents in comparison to untreated controls following 6 days of incubation. Sixty‐one fresh breast cancer specimens upon testing yielded an evaluability rate of 95%. Forty‐seven of the tumors were untreated primary breast cancers, the remaining 14 were from patients with metastatic disease. Correlations of in vitro drug sensitivity with in vivo response were obtained for 17 treatment regimens in 14 patients with metastatic breast cancer. The level of sensitivity was 90% and the specificity 86%. These preliminary data demonstrated the ATP‐CVA to be a practical in vitro approach to breast cancer testing. It will require a larger clinical study for confirmation. © 1993 Wiley‐Liss, Inc.
Does gastric adenocarcinoma develop after the treatment of gastric lymphoma?
Authors: Zorlu A. Faruk , Atahan I. Lale , Gedikoglu Gökhan , Ruacan Sevket , Sayek Iskender , Tekuzman Gülten 
Published: February 2007

AbstractTwo adult patients with the diagnosis of gastric lymphoma who developed adenocarcinoma of the stomach 8 years after the treatment are presented. Both patients were treated by subtotal gastrectomy followed by irradiation of 4,000–4,500 cGy to the epigastric region and six courses of chemotherapy (vincristine, cyclophosphamide, prednisolone). In our review of the literature, 16 cases of gastric adenocarcinoma following the treatment of gastric lymphoma were found and listed with details. The factors influencing the development of this secondary carcinoma, mainly those treatment related are discussed. The possible role of both radiotherapy and chemotherapy in shortening the latent period for the development of stump carcinoma is emphasized. © 1993 Wiley‐Liss, Inc.
Sarcoidosis of the pancreas
Authors: Brady Mary S. , Garfein Carol F. , Klimstra David , Brenann Murray F. 
Published: February 2007

AbstractWe report a case of pancreatic sarcoidosis in a patient with radiographic and clinical findings suggestive of pancreatic cancer. Clinically apparent involvement of the pancreas is uncommon in patients with known sarcoidosis and is distinctly unusual as the initial presentation of disease. Sarcoid involvement of the pancreas can mimic adenocarcinoma and should be considered in the differential diagnosis of a pancreatic mass in a patient with symptoms suggestive of sarcoidosis. © 1993 Wiley‐Liss, Inc.
Proliferative activity of gastric cancer assessed by immunostaining for proliferating
Authors: Inada Takao , Imura Joji , Ichikawa Akira , Ogata Yoshiro , Shimamura Kayako 
Published: February 2007

AbstractThe growth activity of 107 gastric carcinomas was assessed by immunohis‐tochemical staining for formalin‐fixed, paraffin‐embedded tissue with a monoclonal antibody against proliferating cell nuclear antigen (PCNA). When the tumor doubling times (Tds) of 10 patients were estimated from the serum levels of carcinoembryonic antigen and carbohydrate antigen 19–9, there was an inverse correlation between the Tds and PCNA labeling index (LI) at P = 0.055. Flow‐cytometric analysis was carried out by double staining for PCNA and DNA using fresh materials from 14 patients. The PCNA‐positive cell fraction revealed by flow cytometry showed a good linear correlation with PCNA LI in routinely stained tissue. The LI of well‐differentiated adenocarcinoma was significantly higher than that of the poorly differentiated type. When the LI was analyzed in well‐ or poorly differentiated adenocarcinoma, the value was significantly higher in the well‐differentiated type with hepatic metastasis and in the poorly differentiated type with lymph node metastasis. © 1993 Wiley‐Liss, Inc.
Surgical management of accessory parotid tumors
Authors: Rodino William , Shaha Ashok R. 
Published: February 2007

AbstractAccessory parotid gland tumors are defined as masses within salivary gland tissue located adjacent to Stensen's duct, but separate from the main body of the parotid gland. These tumors usually present as asymptomatic cheek masses. There is a temptation to excise these masses locally; however, the likelihood of injury to branches of the facial nerve is high. The best surgical approach to tumors in the accessory parotid region is via a standard parotid incision and concomitant superficial parotidectomy. Eight patients have been surgically treated with accessory parotid gland masses. Six patients had mixed tumors, one had a low grade mucoepidermoid carcinoma, and one had a localized parotitis. Our approach included a standard parotid incision, raising an anterior flap beyond the mass, and exposing the main trunk of the facial nerve, with careful tracing of all its branches. This approach to accessory parotid gland tumors is superior in that it provides a better margin of resection and minimizes functional and cosmetic deformities. Most importantly, there is less danger of injury to branches of the facial nerve. © 1993 Wiley‐Liss, Inc.
Primary gastinc lymphoma
Authors: Secco Giovanni B. , Fardelli Roberto , Campora Elisabetta , Munizzi Francesco , Aste Hugo , Nicolò Guido 
Published: February 2007

AbstractThe records of 30 patients with primary gastric lymphoma and a minimum of 5 years of follow‐up were reviewed and clinical and pathologic prognostic factors analyzed. The overall 5‐year survival was 40% (median 23 months). No significant relationship between surgical and patient age, sex, duration of symptoms, macroscopic appearance, or size of the primary lesion or degree of serosal infiltration was demonstrated. Stage of disease and site of primary had an impact on prognosis. Survival was improved in patients with stage I–II disease (P< 0.05) and in patients with primary located in the distal third of the stomach (P< 0.05). Although histology in all three classifications did not correlate well with survival, patients with low‐grade lymphoma according to Kiel showed improved outcome (P< 0.05). Five–year survival of 11 patients with positive lymph nodes, 6 of whom were treated with cytotoxic therapy, was 54% and comparable to that of 7 patients (56%) with no nodal involvement who did not receive chemotherapy after surgery. © 1993 Wiley‐Liss, Inc.
Intratumor heterogeneity of DNA ploidy and correlations with clinical stage and histologic grade in prostate cancer
Authors: Kucuk Omer , Demirer Taner , Gilman‐Sachs Alice , Taw Irene , Mangold Michael , Singh Satinder , Westerman Maxwell P. 
Published: February 2007

AbstractParaffin blocks from 60 patients with prostate cancer were used to study the DNA ploidy patterns by flow cytometry. Nineteen patients had stage A disease, 11 had stage B, 9 had stage C, 20 had stage D, and 1 was of unknown stage. Histologically, 32 of the cancers were well differentiated, 21 were moderately differentiated, and 7 were poorly differentiated. Eighteen patients had an aneuploid or tetraploid (A/T) pattern and 42 had a diploid pattern. Seventy‐one percent (5/7) of patients with poorly differentiated, 48% (10/21) with moderately differentiated, and 9% (3/32) with well‐differentiated histology had A/T patterns (P< 0.01). Forty‐five percent (9/20) of patients with stage D, 44% (4/9) with stage C, 27% (3/11) with stage B, and 5% (1/19) with stage A had A/T patterns (P < 0.05). Nine patients with an A/T pattern also had DNA ploidy studies done on the “benign” part of the specimen. These specimens showed diploid patterns although three of these patients had well‐differentiated tumor in the “benign” designated part of the specimen. One patient with mixed histology had an aneuploid pattern on the poorly differentiated section and a diploid pattern on the well‐differentiated section of the “malignant” designated part of the same specimen. We conclude that prostate cancer patients with non‐diploid tumors have more advanced disease and less differentiated tumors than patients with diploid tumors and that considerable histological and ploidy heterogeneity may be present in different parts of the same paraffin‐embedded specimen. © 1993 Wiley‐Liss, Inc.